Recently, another 2.2 class of improved new drugs led by Leadingpharm have been approved for implied clinical trial approval. This product can be quickly dissolved when placed in the oral cavity, effectively avoiding problems such as vomiting and hiding medicine in patients with schizophrenia. It will provide a new and more convenient medication choice for mental illness patients.

Oral dissolution films (ODF) are a novel drug delivery system that can rapidly dissolve in the oral cavity, making them particularly suitable for patients with swallowing difficulties, the elderly, pediatrics, or bedridden patients, as well as those who cannot easily obtain water. With the acceleration of population aging and the relaxation of fertility policies, oral films have a broader prospect.

Market direction for oral dissolution film development

Leadingpharm focuses on two advantageous dosage forms, oral dissolution film and freeze-dried oral disintegrating tablets, to build Leadingpharm Drug Delivery Platform. Taking the improvement of the new drug application path as the lead, it expands and extends the lifecycle of traditional drug delivery methods, thereby creating new value in drug research and development.

At present, the platform has integrated multiple systems of oral dissolution film prescription processes, with multiple mature prescription systems and corresponding process parameters to ensure film-forming properties and mechanical properties, especially in the areas of oral dissolution film correction, masking technology, and solving adverse taste issues such as bitterness, numbness, and astringency of raw materials. At present, there are more than 30 new leading oral dissolution film projects under research, and multiple varieties have been applied for pilot scale verification, and some products have obtained implied clinical trial licenses one after another.

At present, several new technology platforms of high-end complex formulation are under innovative construction, and we look forward to utilizing more new technological achievements to comprehensively serve more pharmaceutical enterprises both domestically and internationally